Evidence map›Paper›PMID 39123422›Full record

ArticleCancers2024

Predictive and Prognostic

Marcos Cruz-Montijano, Mariano Amo-Salas, Javier Cassinello-Espinosa, Iciar García-Carbonero, Jose Carlos Villa-Guzman, Ana Maria Garcia-Vicente

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marcos Cruz-MontijanoNuclear Medicine Department, University Hospital of Toledo, 45007 Toledo, Spain.
Mariano Amo-SalasMathematics Department, Universidad de Castilla-La Mancha, 13071 Ciudad Real, Spain.ORCID 0000-0002-0956-2531
Javier Cassinello-EspinosaOncology Department, University Hospital of Guadalajara, 19002 Guadalajara, Spain.
Iciar García-CarboneroOncology Department, University Hospital of Toledo, 45007 Toledo, Spain.
Jose Carlos Villa-GuzmanOncology Department, University Hospital of Ciudad Real, 13005 Ciudad Real, Spain.
Ana Maria Garcia-VicenteNuclear Medicine Department, University Hospital of Toledo, 45007 Toledo, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe aimed to develop a nomogram able to predict treatment failure, skeletal events, and overall survival (OS) in patients with castration-resistant prostate cancer with bone metastases (CRPC-BM) treated with Radium-223 dichloride ( PATIENTS AND

methodsPatients from the Castilla-La Mancha Spanish region were prospectively included in the ChoPET-Rad multicenter study from January 2015 to December 2022. Patients underwent baseline, interim, and end-of-treatment bone scintigraphy (BS) and

resultsMedian progression-free survival (PFS) and OS were 4 and 14 months (mo), respectively. The variables that showed independent and significant association with therapeutic failure were baseline alkaline phosphatase (AP) levels (

conclusionsFCH PET/CT appears to be a good tool for evaluating patients eligible for treatment with

Indexed as

18F-fluorocholine PET/CTbone scintigraphycastration-resistant prostate cancer with bone metastases (CRPC-BM)nomogramoverall survivalradiomicsradium-223 dichloridetherapeutic failure

Identifiers

PMID39123422
PMCPMC11312125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.